Why argenx SE (ARGX) Stock Is Down Today

argenx SE (ARGX) is down 3.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is a mix of profit-taking after last week’s sharp rally and a fresh analyst downgrade on August 24, 2026. There does not appear to be a new company-specific negative announcement today, so the move looks more tied to sentiment and positioning than to a fundamental setback.

Details:

argenx announced positive Phase 3 ALKIVIA topline results on August 17, with efgartigimod meeting the primary endpoint in autoimmune myositis and showing statistically significant improvement in the combined study population.

That clinical update helped drive a strong run in the shares last week, which can set up a pullback as traders lock in gains after a sharp move higher.

An analyst downgrade to Hold surfaced on August 24, which may have added pressure and encouraged investors to step back after the recent rally.

Separate from today’s drop, argenx is also in the middle of a tender offer to acquire Forte Biosciences for $77.00 per share, adding another capital-allocation topic for investors to weigh.

Sources:

argenx, StreetInsider, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ARGX Hedge Fund Activity

We have seen 266 institutional investors add shares of $ARGX stock to their portfolio, and 275 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ removed 696,908 shares (-20.6%) from their portfolio in Q2 2026, for an estimated $646,570,335
CORIENT PRIVATE WEALTH LLC removed 244,317 shares (-99.1%) from their portfolio in Q1 2026, for an estimated $178,412,489
FMR LLC added 240,418 shares (+4.8%) to their portfolio in Q2 2026, for an estimated $223,052,607
BESSEMER GROUP INC added 203,528 shares (+316.8%) to their portfolio in Q2 2026, for an estimated $188,827,172
INVESCO LTD. removed 150,707 shares (-25.3%) from their portfolio in Q2 2026, for an estimated $139,821,433
BARCLAYS PLC added 128,927 shares (+2344.1%) to their portfolio in Q2 2026, for an estimated $119,614,602
FIERA CAPITAL CORP removed 126,775 shares (-58.4%) from their portfolio in Q2 2026, for an estimated $117,618,041

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ARGX Congressional Stock Trading

Members of Congress have traded $ARGX stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ARGX stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ARGX Price Targets

Multiple analysts have issued price targets for $ARGX recently. We have seen 11 analysts offer price targets for $ARGX in the last 6 months, with a median target of $1014.0.

Here are some recent targets:

Luca Issi from RBC Capital set a target price of $945.0 on 07/07/2026
Tazeen Ahmad from B of A Securities set a target price of $1088.0 on 07/02/2026
Douglas Tsao from HC Wainwright & Co. set a target price of $940.0 on 06/25/2026
Matthew Harrison from Morgan Stanley set a target price of $1180.0 on 06/24/2026
David Nierengarten from Wedbush set a target price of $1000.0 on 06/11/2026
Derek Archila from Wells Fargo set a target price of $1291.0 on 06/01/2026
Gavin Clark-Gartner from Evercore ISI Group set a target price of $1059.0 on 05/15/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.